• Earlier this month at the American Diabetes Association’s Scientific Sessions in New Orleans, DexCom reported CONNECT trial results showing its G7 continuous glucose monitor significantly lowered A1C and improved glucose control in adults with Type 2 diabetes not using insulin compared with traditional finger-stick testing.
• The breadth of benefit across demographics and medication regimens suggests DexCom’s CGM technology could be relevant to a much wider Type 2 population than historically targeted, while the Stelo app upgrade and planned Nutrisense acquisition point to a broader metabolic health ecosystem beyond glucose data alone.
• We’ll now examine how the CONNECT trial’s benefits for non‑insulin Type 2 patients may reshape DexCom’s investment narrative and outlook.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

DexCom Investment Narrative Recap

To own DexCom, you need to believe continuous glucose monitoring can keep expanding beyond intensive insulin users, supported by growing coverage and strong clinical evidence. The CONNECT data reinforces the key near term catalyst of broader Type 2 adoption, especially in the large non insulin segment, while competitive pressure and potential CMS pricing changes still look like the most important risks. Overall, this news supports the existing growth thesis rather than materially changing it.

Among DexCom’s recent moves, the planned Nutrisense acquisition feels most connected to the CONNECT results. If G7 can help a wider Type 2 population improve A1C, then pairing sensors with app based nutrition guidance and coaching could matter for keeping those users engaged over time. That, in turn, goes straight to the heart of DexCom’s main catalyst: converting newly covered lives into long term, active CGM users.

Yet despite this encouraging trial, investors should still pay attention to the risk that potential CMS competitive bidding could squeeze CGM pricing and...

DexCom's narrative projects $6.7 billion revenue and $1.4 billion earnings by 2029. This requires 11.7% yearly revenue growth and an earnings increase of about $0.5 billion from $930.4 million today.

Uncover how DexCom's forecasts yield a $83.42 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Compared with the consensus view, the most pessimistic analysts were assuming about US$6.4 billion in 2029 revenue and US$1.4 billion in earnings, so CONNECT’s non insulin data and broader coverage progress could eventually challenge that cautious stance if adoption trends start to look stronger than those earlier forecasts.

Explore 6 other fair value estimates on DexCom - why the stock might be worth as much as 56% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your DexCom research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free DexCom research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DexCom's overall financial health at a glance.

Want Some Alternatives?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Find 44 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.